Welcome to our dedicated page for X4 Pharmaceuticals news (Ticker: XFOR), a resource for investors and traders seeking the latest updates and insights on X4 Pharmaceuticals stock.
X4 Pharmaceuticals, Inc. (Nasdaq: XFOR) is a late-stage clinical biopharmaceutical company committed to the development of novel therapeutics aimed at improving immune cell trafficking and reversing immune suppression. The company's core focus is on treating rare diseases and conditions resulting from immune system dysfunction, including cancer and genetic primary immunodeficiency diseases.
X4’s lead clinical candidate, mavorixafor, is a selective, small-molecule antagonist of the chemokine receptor CXCR4. Designed as an oral, once-daily therapy, mavorixafor targets immune cell mobilization and has shown promising results in clinical trials. It is currently under priority review by the FDA for the treatment of WHIM (Warts, Hypogammaglobulinemia, Infections, and Myelokathexis) syndrome, a rare primary immunodeficiency. The company’s recent NDA submission is supported by positive results from the global, pivotal 4WHIM Phase 3 clinical trial, which demonstrated mavorixafor's ability to reduce infection rates and improve immune cell counts without serious adverse events.
In addition to mavorixafor for WHIM syndrome, X4 is advancing its pipeline with ongoing investigations for mavorixafor in chronic neutropenic disorders and other immunodeficiencies. The company has also initiated preclinical development of other CXCR4 antagonists, including X4P-002 and X4P-003, to address different properties and mechanisms within the immune system.
Headquartered in Boston, Massachusetts, with a research center in Vienna, Austria, X4 leverages its deep understanding of CXCR4 biology to innovate and bring transformative therapies to patients with limited treatment options. The company's mission is driven by a commitment to improve the lives of those affected by rare and severe immune diseases through rigorous scientific research and strategic investment in its proprietary pipeline.
For more updates and detailed information, visit X4 Pharmaceuticals.
X4 Pharmaceuticals (Nasdaq: XFOR) announced inducement awards to new employees under the 2019 Inducement Equity Incentive Plan on December 31, 2021. The awards comprise options for 37,650 shares, with an exercise price of $2.40 per share, equal to the closing price on January 4, 2022. The options will vest over four years, with 25% vesting after one year. X4 focuses on developing novel therapies targeting the CXCR4 pathway, particularly for rare diseases. Its lead candidate, mavorixafor, is being evaluated in multiple clinical trials, including a Phase 3 trial for WHIM syndrome.
X4 Pharmaceuticals (Nasdaq: XFOR) recently presented positive findings on mavorixafor at the ASH Annual Meeting. The data indicates that mavorixafor effectively raises white blood cell counts across various diseases, including Chronic Neutropenia and WHIM syndrome, showcasing sustained improvements in infection rates. Notably, mavorixafor has been well tolerated in ongoing clinical trials. A virtual seminar on this topic is scheduled for December 16, 2021. Results from a global Phase 3 trial in WHIM syndrome are expected by Q4 2022.
X4 Pharmaceuticals (Nasdaq: XFOR) announced positive interim results from its ongoing Phase 1b trial of mavorixafor in combination with ibrutinib for patients with Waldenström’s macroglobulinemia (WM) and specific mutations. The trial has achieved a remarkable 100% overall response rate in evaluable patients. After 12 months, patients saw significant reductions in serum IgM levels, with median decreases from 47.2 g/L to 7.73 g/L. Further data, including responses from refractory patients, is expected throughout 2022.
X4 Pharmaceuticals (Nasdaq: XFOR) is set to host a virtual seminar titled “Understanding Primary Immunodeficiencies” on December 16, 2021, at 8:30 a.m. EST. The seminar aims to showcase new clinical data on mavorixafor, their leading candidate for treating immunodeficiencies, particularly in the context of WHIM syndrome. Esteemed guest speakers include experts such as Neal Sondheimer, M.D., and Theresa Tarrant, M.D. The event will also highlight relevant research from the upcoming ASH Annual Meeting. A live webcast will be available on the company's website.
X4 Pharmaceuticals, Inc. (Nasdaq: XFOR) announced on December 1, 2021, that its Compensation Committee granted inducement awards to new employees. These awards include options for 17,000 shares and restricted stock units for 25,000 shares under the 2019 Inducement Equity Incentive Plan. The options have a ten-year term with an exercise price of $4.45 per share, vesting over four years. X4 focuses on developing CXCR4-targeted therapies, notably mavorixafor, which is undergoing clinical trials for various immune system diseases.
X4 Pharmaceuticals (Nasdaq: XFOR) announced its participation in the Stifel 2021 Virtual Healthcare Conference on November 17, 2021, at 11:20 AM ET. The event will feature a fireside chat, which will be available via live webcast on X4's investor website. X4 is focused on developing novel CXCR4-targeted therapies for immune system diseases, with mavorixafor as its lead candidate. The company is advancing mavorixafor through various clinical trials for conditions including primary immunodeficiencies and certain cancers. The archived event will be accessible for 90 days post-conference.
X4 Pharmaceuticals, Inc. (Nasdaq: XFOR) reported significant advancements in its WHIM syndrome treatment, mavorixafor, including the completion of enrollment in a pivotal Phase 3 trial. The company anticipates top-line data in Q4 2022. Recent findings indicate a potential U.S. WHIM patient population of 3,700, with mavorixafor demonstrating increased neutrophil levels and good tolerability. Financial results show a net loss of $20.2 million for Q3 2021, up from $17.4 million year-over-year. An Investor Day is scheduled for December 16, highlighting further clinical data.
X4 Pharmaceuticals (Nasdaq: XFOR) announced on November 1, 2021, that its Compensation Committee granted inducement awards to new employees under the 2019 Inducement Equity Incentive Plan. The awards include options to purchase 11,050 shares of common stock at an exercise price of $4.84 per share, matching the stock's closing price on October 29, 2021. Options vest over four years, with a quarter vesting after one year. X4 focuses on CXCR4-targeted therapies for immune system diseases, with its lead candidate mavorixafor currently undergoing multiple clinical trials.
X4 Pharmaceuticals (Nasdaq: XFOR) announced its upcoming earnings call on November 4, 2021, at 9:05 a.m. ET. The call will cover the third quarter financial results and recent business highlights. Additionally, the company is expected to discuss abstracts accepted for the 63rd American Society of Hematology (ASH) Annual Meeting, with publication set for the same day at 9:00 a.m. ET. X4 is focused on developing mavorixafor, a novel CXCR4-targeted therapy, currently undergoing clinical trials for various rare diseases.
X4 Pharmaceuticals has appointed Françoise de Craecker to its Board of Directors and hired Karolyn Park as Vice President, U.S. Commercial. These strategic moves aim to enhance the company's leadership as it prepares for the anticipated U.S. launch of its lead candidate, mavorixafor. De Craecker brings over 30 years of experience in launching rare disease products globally, while Park has nearly 20 years in life science marketing. The hiring is viewed as a critical step in maximizing mavorixafor's potential to treat immunodeficiencies and cancers.
FAQ
What is the current stock price of X4 Pharmaceuticals (XFOR)?
What is the market cap of X4 Pharmaceuticals (XFOR)?
What does X4 Pharmaceuticals specialize in?
What is mavorixafor?
What is WHIM syndrome?
What are the latest developments for X4 Pharmaceuticals?
What other conditions is mavorixafor being investigated for?
Where is X4 Pharmaceuticals headquartered?
Has mavorixafor received any special designations from regulatory bodies?
What are the promising indications from the 4WHIM Phase 3 clinical trial?
What other products are in X4 Pharmaceuticals' pipeline?
How can I stay updated on X4 Pharmaceuticals' progress?
